Chargement en cours...
Palbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR+/HER2– Advanced Breast Cancer
With more than 6 years of follow‐up in the phase III PALOMA‐3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR‐positive, HER2‐negative advanced breast cancer that progressed on prior endocrine therapy....
Enregistré dans:
| Publié dans: | Oncologist |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley & Sons, Inc.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262313/ https://ncbi.nlm.nih.gov/pubmed/34152059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13864 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|